MARKET

GRFS

GRFS

Grifols S A
NASDAQ
9.76
-0.03
-0.31%
Opening 15:04 11/28 EST
OPEN
9.89
PREV CLOSE
9.79
HIGH
9.98
LOW
9.71
VOLUME
554.91K
TURNOVER
0
52 WEEK HIGH
10.97
52 WEEK LOW
6.50
MARKET CAP
6.62B
P/E (TTM)
1134.88
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at GRFS last week (1120-1124)?
Weekly Report · 1d ago
Weekly Report: what happened at GRFS last week (1113-1117)?
Weekly Report · 11/20 09:27
Weekly Report: what happened at GRFS last week (1106-1110)?
Weekly Report · 11/13 09:25
GigaGen, A Subsidiary Of Grifols Presents IND-Enabling Data And Phase 1 Trial Strategy For Its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, At SITC 2023
Gigagen's oncology candidate, giga-564, is a differentiated anti-ctla-4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities. national cancer institute researchers will conduct the first-in-human phase 1 trial. gigagen anticipates trial initiation in 2024.
Benzinga · 11/06 13:20
Weekly Report: what happened at GRFS last week (1030-1103)?
Weekly Report · 11/06 09:26
Kepler Capital Sticks to Their Buy Rating for Grifols SA (GRFS)
TipRanks · 11/04 01:35
Grifols S A: Report of foreign issuer
Press release · 11/02 18:08
Grifols S.A. reports Q3 results
Seeking Alpha · 11/02 13:40
More
About GRFS
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.

Webull offers Grifols SA - ADR stock information, including NASDAQ: GRFS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRFS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GRFS stock methods without spending real money on the virtual paper trading platform.